Q-omics provides the consensus-scored SNORA63C profile across patient tissues and cancer cell-line models. SNORA63C expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, SNORA63C is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, SNORA63C RNA expression shows 13,626 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight READ, LIHC, and LUAD as cancer lineages where SNORA63C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA63C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA63C survival associations across molecular data types. SNORA63C RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA63C RNA expression–survival associations across cancer types. High SNORA63C expression shows unfavorable associations in READ, KIRC, LUSC and LGG, but favorable associations in HNSC and COAD. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify READ as the clearest survival context for SNORA63C RNA expression.
This table summarizes SNORA63C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA63C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA63C shows lower tumor expression in COAD and higher tumor expression in LIHC, CHOL, HNSC and KIRC. The LIHC box plot shows higher SNORA63C RNA expression in tumor versus normal tissue (log2 FC = +0.218, t-test p = .016).
This table shows molecular features associated with SNORA63C in patient tissues and cancer cell lines. In patient samples, SNORA63C shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
